X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs ALEMBIC LTD - Comparison Results

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES ALEMBIC LTD ALKEM LABORATORIES/
ALEMBIC LTD
 
P/E (TTM) x - 51.1 - View Chart
P/BV x 6.6 2.2 300.9% View Chart
Dividend Yield % 0.7 0.5 141.2%  

Financials

 ALKEM LABORATORIES   ALEMBIC LTD
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
ALEMBIC LTD
Mar-18
ALKEM LABORATORIES/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs1,58972 2,206.9%   
Low Rs1,23234 3,634.2%   
Sales per share (Unadj.) Rs417.54.7 8,881.0%  
Earnings per share (Unadj.) Rs56.36.1 922.3%  
Cash flow per share (Unadj.) Rs64.76.2 1,036.1%  
Dividends per share (Unadj.) Rs12.700.20 6,350.0%  
Dividend yield (eoy) %0.90.4 238.4%  
Book value per share (Unadj.) Rs292.940.7 720.4%  
Shares outstanding (eoy) m119.57267.03 44.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.411.3 30.0%   
Avg P/E ratio x25.18.7 288.8%  
P/CF ratio (eoy) x21.88.5 257.1%  
Price / Book Value ratio x4.81.3 369.8%  
Dividend payout %22.63.3 688.5%   
Avg Mkt Cap Rs m168,65314,139 1,192.8%   
No. of employees `000NANA-   
Total wages/salary Rs m9,171207 4,422.0%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m49,9151,255 3,976.7%  
Other income Rs m1,645370 444.4%   
Total revenues Rs m51,5611,625 3,172.2%   
Gross profit Rs m8,482111 7,634.8%  
Depreciation Rs m1,00638 2,660.8%   
Interest Rs m6712 39,447.1%   
Profit before tax Rs m8,451442 1,912.9%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,60624 6,705.6%   
Profit after tax Rs m6,7311,630 413.0%  
Gross profit margin %17.08.9 192.0%  
Effective tax rate %19.05.4 350.6%   
Net profit margin %13.5129.8 10.4%  
BALANCE SHEET DATA
Current assets Rs m27,0621,867 1,449.4%   
Current liabilities Rs m15,324591 2,591.9%   
Net working cap to sales %23.5101.6 23.1%  
Current ratio x1.83.2 55.9%  
Inventory Days Days6794 70.6%  
Debtors Days Days4174 56.1%  
Net fixed assets Rs m12,6101,791 704.1%   
Share capital Rs m239534 44.8%   
"Free" reserves Rs m34,49010,324 334.1%   
Net worth Rs m35,02710,858 322.6%   
Long term debt Rs m1,21241 2,940.8%   
Total assets Rs m54,38711,591 469.2%  
Interest coverage x13.6260.9 5.2%   
Debt to equity ratio x00 911.6%  
Sales to assets ratio x0.90.1 847.5%   
Return on assets %13.614.1 96.7%  
Return on equity %19.215.0 128.0%  
Return on capital %24.915.2 163.6%  
Exports to sales %12.91.5 837.5%   
Imports to sales %3.121.0 14.7%   
Exports (fob) Rs m6,46119 33,304.6%   
Imports (cif) Rs m1,540263 584.9%   
Fx inflow Rs m6,56319 33,831.4%   
Fx outflow Rs m3,012264 1,141.6%   
Net fx Rs m3,552-244 -1,453.1%   
CASH FLOW
From Operations Rs m7,259236 3,078.2%  
From Investments Rs m1,864-224 -832.2%  
From Financial Activity Rs m-9,273-27 34,859.8%  
Net Cashflow Rs m-150-15 1,013.5%  

Share Holding

Indian Promoters % 66.9 64.0 104.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 0.2 16,550.0%  
FIIs % 0.0 9.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 26.1 -  
Shareholders   68,381 54,701 125.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   DR. DATSONS LABS  DISHMAN PHARMA  TTK HEALTHCARE  ASTRAZENECA PHARMA  BIOCON LTD  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 190 Points Higher; Consumer Durable and Healthcare Stocks Witness Buying(Closing)

After trimming sharp losses in the afternoon session, Indian share markets continued to witness buying interest and ended the day on a positive note.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (2QFY19); Net Profit Up 4.0% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Dec 11, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS